Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Alan Langerak (NPI 1902853294)

Field	Value
Entity Type	Individual
Organization	Alan Langerak
Address	5430 Landmark Ln
City	Prescott
State	AZ
ZIP	86301
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 30, 2006

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider’s Medicare volume dominates its payer mix: lifetime Medicare revenue is $2.7M while there is no Medicaid billing on file, so ALAN LANGERAK operates effectively as a Medicare-focused practice rather than a dual-payer clinic. The absence of Medicaid claims suggests limited exposure to that program and concentrated reliance on Medicare reimbursement for the practice’s financial performance.

Revenue is highly concentrated in a small number of infusion biologics: the precomputed top-3 codes account for 69.1% of total Medicare revenue, driven by J9271 (29.6% of Medicare revenue), J9144 (28.3%), and J0897 (11.2%). This concentration means a handful of high-cost injectable therapies — rather than broad primary-care E/M services — are the primary revenue drivers for the practice.

The code mix and descriptions indicate a clinic centered on oncology infusion and supportive oncology care: J9271 (pembrolizumab) and J9144 (daratumumab) are in the top revenue slots and are infused cancer immunotherapy/monoclonal antibody agents, while J0897 (denosumab) is commonly used for bone-related oncology indications. High-volume chemotherapy administration codes such as 96413 and add-on infusion codes (96417, 96365) further reinforce that this is an active infusion center providing repeated office-based systemic therapy.

Competitive standing is mixed across specific products: the provider’s J9144 volume ranks #51 of 615 nationally (92nd percentile), indicating a relatively strong national position for daratumumab administration, while J9271 ranks #502 of 1841 (72nd percentile) and is described as "typical, unremarkable volume." J0897 is in the 95th percentile and labeled "notably above typical national volume," showing above-average national activity for that supportive agent.

Several codes are statistical outliers for utilization and suggest unusually high throughput of certain services: 99214 is an "extreme outlier, far above typical national volume" at the 99th percentile, and 96523 (irrigation of venous access device) ranks #3 of 1643 providers (100th percentile, labeled "extreme outlier"). Additional high-percentile procedure codes include 96413 (96th percentile, "notably above typical national volume") and 96375 (98th percentile, "notably above typical national volume"). These outliers point to sustained, high-frequency procedural and infusion workflows in the practice.

Although infusion biologics dominate revenue, supportive services and biosimilars also appear in the top code list: Q5119 (rituximab biosimilar), Q5118 (bevacizumab biosimilar) and Q5122 (pegfilgrastim biosimilar) together contribute measurable revenue and rank in moderate-to-high national percentiles, reflecting use of biosimilar alternatives and a diversified drug mix within the infusion portfolio. This pattern is consistent with an oncology practice managing both core monoclonal antibody therapies and associated growth-factor or supportive agents.

Imaging and model-based care payments are present but represent modest shares of revenue: PET/CT code 78815 contributes $97.8K (3.7% of Medicare revenue) and ranks in the 64th percentile ("typical, unremarkable volume"), while A9552 (FDG dose) and 78816 are smaller contributors. The practice’s M0010 Enhanced Oncology Model monthly payments are also included ($18.3K, 0.7% of Medicare revenue) and rank at the 94th percentile, indicating participation in oncology care models and some engagement with value-based or programmatic payment structures.

The provider has longstanding enrollment in Medicare (NPI enumerated 2006-05-30, ~20 years ago), indicating an established practice footprint; combined with the heavy Medicare revenue dependence and concentration in a few high-revenue infusion codes, this profile suggests the business model is an experienced, clinic-based oncology/hematology infusion practice whose financial performance is closely tied to the continued use and reimbursement of specific biologic therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

59 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,000	$40	$774K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	19,440	$40	$738.7K
J0897	Injection, denosumab, 1 mg	16,200	$20	$291.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,620	$90	$147.8K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	90	$1,120	$97.8K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,270	$20	$71.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	700	$100	$69.9K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	2,930	$20	$67.4K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	590	$90	$52.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	17,780	$1	$35.6K

Showing 1–10 of 59

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 59 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Alan Langerak — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

59 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	80	10,000	$40	$487.4K
J9144	2	40	8,370	$40	$349.9K
J0897	28	260	2,940	$20	$115.6K
78815	54	160	60	$710	$75.8K
Q5118	5	20	1,290	$20	$44.4K
Q5119	5	40	1,480	$20	$42.6K
Q5122	2	10	410	$90	$36.5K
J1437	2	20	1,600	$20	$26.5K
96413	15	230	190	$100	$24.8K
J0881	6	50	7,000	$1	$23.1K

Showing 1–10 of 59

Related Providers

Other providers that share a Tax Identification Number (TIN) with Alan Langerak, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Oncology Associates PC	AZ	Specialist	$0	$13.9M
Iyad Hamarneh	AZ	Medical Oncology Physician	$3.5M	$0
Peter Mathern	AZ	Medical Oncology Physician	$3M	$0
Charles Taylor	OK	Hematology & Oncology Physician	$2.3M	$0
Allan Espinosa Morazan	AZ	Medical Oncology Physician	$2.2M	$0
Laurie Chen	AZ	Hematology & Oncology Physician	$1.6M	$0
Donn Davis	AZ	Radiation Oncology Physician	$1.2M	$0
Akhilesh Sharma	AZ	Infectious Disease Physician	$1.2M	$0
Sharon Ondreyco	AZ	Hematology & Oncology Physician	$1.1M	$0
Rezwan Chowdhury	AZ	Radiation Oncology Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Alan Langerak, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Yavapai Community Hospital Association	AZ	General Acute Care Hospital	$0	$66.2M
Prescott Healthcare Solutions LLC	AZ	Family Medicine Physician	$0	$13.3M
Summit Behavioral Health Of Az, LLC	AZ	Substance Abuse Rehabilitation Facility	$0	$13.3M
Medical Services Of Prescott, Inc.	AZ	Emergency Medicine Physician	$0	$12.3M
Prescott Whipple Stage	AZ	Taxi	$0	$9.2M
Prescott Outpatient Surgical Center LLC	AZ	Ambulatory Surgical Clinic/Center	$1.7M	$25.7K
Arizona Institute Of Eye Surgery LLC	AZ	Ambulatory Surgical Clinic/Center	$1.4M	$24.7K
Ayad Agha	AZ	Diagnostic Radiology Physician	$1M	$0
Ajith Purush	AZ	Internal Medicine Physician	$807.3K	$0
Ray Johnson	AZ	Dermatology Physician	$708.7K	$0

Alan Langerak — Billing Profile & Reimbursement Data

Sign up for Alan Langerak — Billing Profile & Reimbursement Data policy alerts

Alan Langerak — Billing Profile & Reimbursement Data

Sign up for Alan Langerak — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References